Table 3.

Comparison of PROs by amyloid organ involvement

Domain	Measure	Cardiac AL (Yes=171, N=126)		Neurologic AL (Yes=90, N=207)		Renal AL (Yes=171, No=126)
		Cohen’s d (yes vs no)	p- value	Cohen’s d (yes vs no)	p-value	Cohen’s d (yes vs no)	p- value
Physical Function	PROMIS Physical Function-4	−0.3	0.02	−0.3	0.02	0.1	0.6
	SF-36 Physical Functioning	−0.3	0.02	−0.2	0.1	0.1	0.5
	SF-36 Role Physical	−0.2	0.1	−0.3	0.03	−0.2	0.1
Fatigue	PROMIS Fatigue-4	0.2	0.1	0.3	0.02	0.2	0.2
	PROMIS Fatigue-8	0.1	0.3	0.2	0.08	0.2	0.1
	SF-36 Vitality	−0.3	0.01	−0.3	0.02	−0.1	0.4
Social Roles	PROMIS Ability to Perform Social Roles and Activities	−0.2	0.1	−0.3	0.03	−0.1	0.6
	SF-36 Social Function	−0.1	0.3	−0.2	0.1	−0.2	0.1
Pain	PROMIS Pain Interference	0.1	0.5	0.5	<0.001	0.3	0.01
	SF-36 Bodily Pain	−0.05	0.68	−0.51	<0.001	−0.3	0.03
Sleep	PROMIS Sleep Disturbance	0.2	0.1	0.3	0.02	0.05	0.7
Mental Health	PROMIS Anxiety	0	0.8	0	0.9	0.1	0.4
	PROMIS Depression	−0.1	0.5	0.2	0.1	0.1	0.3
	PROMIS Cognitive Function	0	>0.9	−0.2	0.3	−0.1	0.3
	SF-36 Mental Health	0	0.9	0	0.9	−0.3	0.04
	SF-36 Role Emotional	0.1	0.7	−0.1	0.5	−0.3	0.04
Summary scores and Other	PROMIS GPSS	−0.2	0.05	−0.4	<0.001	0	0.8
	PROMIS GMSS	−0.1	0.3	−0.3	0.03	−0.2	0.1
	SF-36 PCS	−0.3	0.03	−0.4	0.002	−0.1	0.3
	SF-36 MCS	−0.2	0.1	−0.3	0.06	−0.2	0.06
	SF-36 General Health	−0.3	0.01	−0.4	0.002	0.1	0.7

KCCQ-12 was only administered to individuals reporting cardiac amyloidosis and it is not relevant for renal or neurologic conditions. Therefore, it is not shown in this table

Interpretation of Cohen’s d: 0.2- small, 0.5- medium, and 0.8- large effect sizes [22]